Advertisement

Curis Inc. has $6 million more in its coffers from a milestone payment after its collaborator Roche submitted its small molecule cancer drug candidate, vismodegib, to the European Medicines Agency for approval in treating advanced basal cell carcinoma.

SOURCE

Advertisement
Advertisement